Eli Lilly and Co. reported on Thursday that its revenue for the fourth quarter of 2024 surged 45% year-over-year to $13.5 billion, exceeding expectations. Net income came to $4.4 billion, soaring 101% annually, with earnings per share (EPS) jumping 102% to $4.88. In the full-year 2024, Eli Lilly posted a 32% increase in revenue to $45 billion, and a 102% rise in net income to $10.5 billion and EPS to $5.20. The company said it expects 2025 revenue to be between $58 billion and $61 billion and an EPS of $22.05 to $23.55.
"We enter 2025 with tremendous momentum and look forward to strong financial performance and several important Phase 3 readouts which, if positive, will further accelerate our long-term growth," CEO David Ricks said.
Eli Lilly's stock gained 2.12% in premarket trade after the earnings release.
